New York, NY, USA, December 18th, 2025, NewsDirect
U.S. aesthetics industry’s measured growth driven by demand for neurotoxins and GLP-1s, signaling shifting patient demand and a maturing industry
- Total non-surgical U.S. spend was $20.5 billion in 2024
- Neurotoxins continue to grow moderately, especially among Gen X and Millennials
- Dermal fillers down 3% y-o-y: legacy products lost share, new fillers growing respectably
- Biostimulatory injectables and medical weight loss are emerging growth segments
- Regionally, the Midwest performed best and saw growth while showing signs of saturation
- Consolidating platforms and PE expected to drive integration and value creation
- New operational challenges in clinical settings include skilled labor acquisition and retention
Guidepoint Qsight, a leading provider of data and analytics services for the medical aesthetics sector, and Skytale, a leading investment banking and management consulting firm serving healthcare and consumer businesses, have released a new edition of their seminal report on the state of the U.S. aesthetics industry, a guide through its transition from rapid post-pandemic expansion into a new phase of maturity.
The report cites that the U.S. aesthetics industry had a strong 2024, growing 5% year-over-year from 2023, bringing total U.S. non-surgical spending to $20.5 billion. This follows a pattern of strong growth since the market contraction in 2020. Certain segments saw more growth than others; however, neurotoxins continued on their upward trajectory, while legacy categories such as dermal fillers and energy-based devices saw more mixed performance.
“Aesthetics continues to grow, but the drivers look different than they did just a few years ago,” said Andrew Mantis, General Manager of Guidepoint Qsight. “Neurotoxins are still outperforming, while other categories recalibrate and patient preferences evolve. It reflects a sector moving from rapid expansion into true maturity.”
Various factors, including the 55% growth of GLP-1 weight loss drugs in 2024, have fueled a shift in the aesthetics market, with investors becoming increasingly attuned to revenue diversification and quality, patient loyalty and retention, and average spend per patient. The report includes an analysis of practices by region and by patient retention, spend, gender, and generational cohort.
“We’ve seen a significant uptick in deal volumes, signaling that private equity firms have a significant amount of capital available for strategically investing in emerging industries such as medical aesthetics,” said Ben Hernandez, CEO and Managing Director of Skytale. “As the medical aesthetics market continues to mature and more private equity sponsors build platforms, the focus on data collection and aggregation will be a primary focal point as larger groups look to grow strategically and implement change across their organizations. This continued data collection will be instrumental in enhancing the medical aesthetic industry.”
To download the full report, users can click here.
About Guidepoint Qsight
Built on a foundation of proprietary healthcare data, Guidepoint Qsight is dedicated to providing unparalleled data and analytics solutions that empower businesses in the aesthetics, medical technology, and medical device industries to make strategic, data-driven decisions. By combining comprehensive market intelligence with innovative technology, Qsight delivers reliable and consistent industry insights. This data intelligence enables clients to optimize their sales and marketing strategies, proactively prepare for and respond to ever-evolving market dynamics, and achieve their business goals.
About Skytale
Skytale is a leading investment banking, management consulting, and private capital solutions firm offering strategic and advisory services to healthcare and consumer businesses nationwide. Skytale Investment Banking consists of licensed investment bankers who have extensive experience in mergers and acquisitions, while Skytale Management Consulting provides services centered on evidence-based strategy to grow healthcare organizations, and private capital advisory capabilities within healthcare. Our integrated approach is designed to help founders, executives, and investors make informed decisions, scale responsibly, and create long-term value.
Contacts
Meir Kahtan
Meir Kahtan Public Relations
[email protected]
+1 917-864-0800
Senior Marketing Specialist
Lainey Stephenson
Skytale
[email protected]
+1 (480) 510-4372